Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study

作者：Uy G L^*; Goyal S D; Fisher N M; Oza A Y; Tomasson M H; Stockerl Goldstein K; DiPersio J F; Vij R

来源：Bone Marrow Transplantation, 2009, 43(10): 793-800.

DOI：10.1038/bmt.2008.384

• auto-SCT
• stem cell mobilization
• multiple myeloma
• bortezomib

The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active investigation. We conducted a study in 40 patients with bortezomib given sequentially pre-auto-SCT and as maintenance therapy post auto-SCT. Pre-transplant bortezomib was administered for two cycles followed by high-dose melphalan 200 mg/m(2) with auto-SCT of G-CS F-mobilized PBMCs. Post transplant bortezomib was administered weekly for 5 out of 6 weeks for six cycles. No adverse effects were observed on stem cell mobilization or engraftment. An overall response rate of 83% with a CR + very good partial remission (VGPR) of 50% was observed with this approach. Three-year Kaplan-Meier estimates of disease-free survival and overall survival (OS) were 38.2 and 63.1%, respectively. Bortezomib reduced CD8(+) cytotoxic T cell and CD56(+) natural killer cell PBL subsets and was clinically associated with high rates of viral reactivation to varicella zoster. Bone Marrow Transplantation (2009) 43, 793-800; doi:10.1038/bmt.2008.384; published online 24 November 2008

• 出版日期2009-5